EZH2 and acute myeloid leukemia: This pathway could be targeted by proteasomal inhibition with bortezomib, which restored EZH2 levels in multi-drug resistant AML cells and led to corresponding reductions in HOX gene expression in this study, promising potential approaches to overcome treatment resistance [25].